Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ATYR
stocks logo

ATYR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast ATYR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATYR is 8.00 USD with a low forecast of 1.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast ATYR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATYR is 8.00 USD with a low forecast of 1.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
7 Hold
0 Sell
Hold
Current: 0.828
sliders
Low
1.00
Averages
8.00
High
20.00
Current: 0.828
sliders
Low
1.00
Averages
8.00
High
20.00
Leerink
Faisal Khurshid
Outperform
maintain
$NULL
2025-09-15
Reason
Leerink
Faisal Khurshid
Price Target
$NULL
2025-09-15
maintain
Outperform
Reason
Leerink analyst Faisal Khurshid keeps an Outperform rating on aTyr Pharma after the company said the Phase 3 EFZO-FIT trial of efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint of steroid reduction. While aTyr plans to engage with the FDA on a potential path forward, Leerink's expectations are low given the primary endpoint miss and unclear relevance of KSQ-Lung score improvements alone, the analyst tells investors in a research note. Going into the readout, the firm expected a primary endpoint miss would see 80%-90% share downside. aTyr Pharma shares are down 82%, or $4.97, to $1.07 in early trading.
Cantor Fitzgerald
Overweight -> Neutral
downgrade
2025-09-15
Reason
Cantor Fitzgerald
Price Target
2025-09-15
downgrade
Overweight -> Neutral
Reason
Cantor Fitzgerald downgraded aTyr Pharma to Neutral from Overweight after the company announced that the Phase 3 pulmonary sarcoidosis trial for efzofitimod missed the primary endpoint of change in mean steroid dose from baseline at week 48. aTyr plans to engage with the FDA to determine the path forward, but the firm doesn't have much confidence in the path forward for efzo in pulmonary sarcoidosis, the analyst tells investors.
Leerink
Faisal Khurshid
Outperform
to
Market Perform
downgrade
$16 -> $1
2025-09-15
Reason
Leerink
Faisal Khurshid
Price Target
$16 -> $1
2025-09-15
downgrade
Outperform
to
Market Perform
Reason
Leerink analyst Faisal Khurshid downgraded aTyr Pharma to Market Perform from Outperform with a price target of $1, down from $16, after the company reported that the Phase 3 EFZO-FIT trial of efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint. The firm had been positive heading into the "highly binary" readout, but tells investors "we were wrong" after topline results showed no statistically significant difference in steroid reduction. The firm isn't sure there is a path forward for efzo given the miss on the primary endpoint and unclear clinical relevance of quality-of-life improvement, the analyst added.
H.C. Wainwright
H.C. Wainwright
Buy -> Neutral
downgrade
2025-09-15
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
2025-09-15
downgrade
Buy -> Neutral
Reason
H.C. Wainwright downgraded aTyr Pharma to Neutral from Buy without a price target after the company's Phase 3 EFZO-FIT study evaluating lead asset efzofitimod for the treatment of pulmonary sarcoidosis missed the primary endpoint. "Many open questions remain regarding a path forward," the analyst tells investors in a research note. The firm cites the lack of regulatory visibility for the downgrade.
JonesResearch
Soumit Roy
Buy
to
Hold
downgrade
2025-09-15
Reason
JonesResearch
Soumit Roy
Price Target
2025-09-15
downgrade
Buy
to
Hold
Reason
JonesResearch analyst Soumit Roy downgraded aTyr Pharma to Hold from Buy without a price target after the Phase 3 EFZO-FIT trial failed to show a significant reduction in change from baseline in mean daily oral corticosteroid dose at week 48 with efzofitimod in patients with pulmonary sarcoidosis. The firm did not expect 40% of patients in the placebo arm to taper to 0mg of steroid at 48 weeks. Jones doubts the FDA will green light efzofitimod with the current dataset and removed the drug from the stock's valuation. aTyr shares could pull back further without a clear decision soon on the fate of its programs, the analyst tells investors in a research note.
Lucid Capital
Buy -> Neutral
downgrade
$11 -> $1
2025-09-15
Reason
Lucid Capital
Price Target
$11 -> $1
2025-09-15
downgrade
Buy -> Neutral
Reason
Lucid Capital downgraded aTyr Pharma to Neutral from Buy with a price target of $1, down from $11, after the Phase 3 EFZO-FIT trial failed to show a significant reduction in change from baseline in mean daily oral corticosteroid dose at week 48 with efzofitimod in patients with pulmonary sarcoidosis. While the data suggests clinical benefit on quality-of-life endpoints, the failure to achieve statistical significance on the primary endpoint "complicates the regulatory path" and the firm prefers to stay on the sidelines pending FDA discussions as it believes shares may remain range-bound until there is more clarity.
See All Ratings

Valuation Metrics

The current forward P/E ratio for aTyr Pharma Inc (ATYR.O) is -1.45, compared to its 5-year average forward P/E of -2.80. For a more detailed relative valuation and DCF analysis to assess aTyr Pharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.80
Current PE
-1.45
Overvalued PE
-1.14
Undervalued PE
-4.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.38
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.57
Undervalued EV/EBITDA
-3.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
481.55
Current PS
0.00
Overvalued PS
1487.39
Undervalued PS
-524.29
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 5978.67% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 5978.67% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ATYR News & Events

Events Timeline

(ET)
2025-11-06
16:23:14
aTyr Pharma Announces Q3 Earnings Per Share of 26 Cents, Exceeding Consensus Estimate of 18 Cents
select
2025-09-30 (ET)
2025-09-30
06:16:31
aTyr Pharma announces positive clinical outcomes for efzofitimod in various diseases
select
2025-09-15 (ET)
2025-09-15
07:34:46
aTyr Pharma Reveals Findings from Phase 3 EFZO-FIT Trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
05:21 AMGlobenewswire
aTyr Pharma Faces Class Action Lawsuit Over Securities Fraud, Stock Plummets 83.2%
  • Lawsuit Notification: Levi & Korsinsky LLP has informed aTyr Pharma investors of a class action lawsuit due to alleged securities fraud occurring between November 2024 and September 2025, aiming to recover losses for affected investors.
  • False Statements Exposed: The complaint alleges that aTyr misled investors by providing overwhelmingly positive statements while concealing significant adverse facts regarding the efficacy of Efzofitimod, damaging the company's reputation and market confidence.
  • Stock Price Crash: Following the announcement on September 15, 2025, that the EFZO-FIT study did not meet its primary endpoint, aTyr's stock plummeted from $6.03 to $1.02, representing an 83.2% decline in a single day, resulting in substantial financial losses for investors.
  • Next Steps: Affected investors must request to be appointed as lead plaintiffs by December 8, 2025, to participate in potential compensation, with no out-of-pocket costs required, highlighting the legal team's commitment to protecting investor rights.
[object Object]
Preview
7.0
04:21 AMGlobenewswire
aTyr Pharma Faces Class Action After 83% Stock Collapse Following Drug Trial Failure
  • Stock Collapse: aTyr Pharma's stock plummeted by 83.2% on September 15, 2025, dropping from $6.03 to $1.02 after its flagship drug Efzofitimod failed to meet its primary trial endpoint, resulting in significant investor losses.
  • Legal Action: Hagens Berman reminds investors that December 8 is the deadline to apply as lead plaintiff in the class action lawsuit, which alleges that aTyr and its executives provided materially false and misleading information about the drug's efficacy, potentially violating securities laws.
  • Clinical Trial Flaws: The lawsuit highlights that aTyr allegedly concealed adverse facts regarding Efzofitimod's ability to allow patients to taper off steroids completely, a key measure of success, which could undermine investor confidence in the company's future prospects.
  • Investor Losses: Hagens Berman has a track record of securing over $2.9 billion in settlements for investors and encourages those who purchased aTyr shares between November 7, 2024, and September 12, 2025, and suffered losses to submit their claims promptly.
[object Object]
Preview
7.0
00:41 AMPRnewswire
Faruqi & Faruqi Investigates aTyr Pharma for Securities Violations
  • Legal Investigation Initiated: Faruqi & Faruqi LLP is investigating potential securities law violations by aTyr Pharma, particularly regarding false statements about its drug Efzofitimod, which may have led to significant investor losses.
  • Stock Price Plummet: Following the release of Efzofitimod study results, aTyr's stock price dropped by 83.25%, from $6.03 on September 12 to $1.01 on September 15, indicating strong market skepticism about the drug's efficacy.
  • Investor Rights Impacted: Due to aTyr's misleading statements, investors purchased shares at artificially inflated prices, resulting in substantial declines in their investment value, prompting Faruqi & Faruqi to urge affected investors to seek legal recourse.
  • Class Action Deadline Approaching: Investors must apply by December 8, 2025, to serve as lead plaintiffs in the class action lawsuit, ensuring their rights are represented in the upcoming litigation.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is aTyr Pharma Inc (ATYR) stock price today?

The current price of ATYR is 0.8278 USD — it has increased 7.39 % in the last trading day.

arrow icon

What is aTyr Pharma Inc (ATYR)'s business?

aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).

arrow icon

What is the price predicton of ATYR Stock?

Wall Street analysts forecast ATYR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATYR is 8.00 USD with a low forecast of 1.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is aTyr Pharma Inc (ATYR)'s revenue for the last quarter?

aTyr Pharma Inc revenue for the last quarter amounts to 190.00K USD, decreased % YoY.

arrow icon

What is aTyr Pharma Inc (ATYR)'s earnings per share (EPS) for the last quarter?

aTyr Pharma Inc. EPS for the last quarter amounts to -0.26 USD, increased 13.04 % YoY.

arrow icon

What changes have occurred in the market's expectations for aTyr Pharma Inc (ATYR)'s fundamentals?

The market is revising Downward the revenue expectations for aTyr Pharma, Inc. (ATYR) for FY2025, with the revenue forecasts being adjusted by -98.52% over the past three months. During the same period, the stock price has changed by -85.24%.
arrow icon

How many employees does aTyr Pharma Inc (ATYR). have?

aTyr Pharma Inc (ATYR) has 56 emplpoyees as of December 05 2025.

arrow icon

What is aTyr Pharma Inc (ATYR) market cap?

Today ATYR has the market capitalization of 81.11M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free